| Name | Title | Contact Details |
|---|
ARKRAY USA is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Preferred Commerce, Inc. (OCBM) is the supplier and provider of Elev8, products that contain some of the world`s most powerful antioxidants and cell reparation enzymes such as SOD (Superoxide Dismutase) mononucleotides and other key ingredients that promote healthier cell activity in all living things. SOD is an enzyme that alternately catalyzes the dismutation (or partitioning) of the superoxide (O2-) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2). Hydrogen peroxide is also damaging and is degraded by other enzymes such as catalase. Preferred Commerce`s specially formulated Elev8 products have been shown to provide relief to people who have Rheumatoid Arthritis, visible signs of skin damage, Scleroderma, Cataracts, Gout, inflammation, Interstitial Cystitis, Osteoarthritis, Parkinson`s Disease, Alzheimer`s disease, and ADHD, not to mention providing a stimulus for overall healthier lifestyles, cardiovascular health, and mental capacity and focus to people without any known health issues. Preferred Commerce has long been a solution provider to the horticulture and agriculture industries, as well as to consumers. In addition, the company has created training and educational products that have fueled billions of dollars in sales for Fortune 500 companies, while its family-friendly how-to-grow products have educated nearly 1 million children on how to successfully grow their own healthy food at home. As today`s health concerns are escalating, Preferred Commerce feels that Elev8 can play an important part in providing people with healthier lifestyles.
Heartbeat Experts is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
At Homethirve, we are dedicated to helping caregivers care for aging seniors with balance, confidence, and support. Discover how our Care Guides can help you!